Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer licenses therapy for autoimmune diseases

This article was originally published in Scrip

Executive Summary

Pfizer is licensing a pre-clinical therapy for patients with rare autoimmune conditions, paying $25 million upfront for what the company sees as a potentially better alternative to a treatment derived from human blood plasma.

You may also be interested in...



Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs

Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.

Mylan CEO Bresch is looking to do a sizable deal

Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.

Biogen's Scangos sees potential to dominate hemophilia market

Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC022937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel